Aptamers are synthetic fragments of nucleic acid polymers which lack genetic information. They are the only known alternative to antibodies. Unlike antibodies, aptamers are synthetically produced, without any trace of endotoxin or other biological impurities as well as showing low immunogenicity.Read More
Apta-1 in clinical phase
Disruptive in-house research showing the aptamer Apta-1’s uniqe multi-mechanistic profile. Apta-1 is currently in clinical phase 1 for the indication sepsis.Read More
Sepsis represents the highest healthcare costs of all critical conditions. In USA the yearly cost is estimated to 62 billion USD for the treatment and care of sepsis patients. Today there is no efficient treatment available.Read More
About Aptahem and sepsis
Aptahem is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase with the main indication sepsis and other acute inflammatory conditions. This medical condition affects yearly 50 million people around the world and is lethal for more than 20-25% of these. Aptahem’s goal is to address the global medical need of treatments for sepsis and critical conditions associated with sepsis.
Today there is no treatment for sepsis or septic shock but only supporting treatment to maintain a healthy blood pressure and to improve oxygenation to prevent organ failure.
Video from Global Sepsis AllianceRead More
6 Mar, 2023Third cohort completed in Aptahem’s FIH study
28 Feb, 2023BioStock article: Further steps in Aptahem’s phase I study
21 Feb, 2023Analyst Groups Aptahem-analys: Gör framsteg i klinik